Publications
84
Citations
1,186
Est. group size
—
Recurring co-author estimate
Active years
32
Publishing since 1994
This name appears to be associated with a mix of research on cancer drug policy and economics, including studies on how cancer drugs are approved, priced, and reimbursed in countries like China, the US, and Australia, alongside work on lung cancer biomarkers and treatment. The publication record also includes unrelated topics such as biohybrid microrobots, gut microbiota, and language development, suggesting the name may represent multiple distinct researchers or highly diverse collaborations rather than a single coherent research program.
Publication output has grown over the last decade, rising from single digits in 2018 to a steady pace of about 12 papers per year from 2023 through 2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Inhalable biohybrid microrobots: a non-invasive approach for lung treatment
Nature Communications · 2025
- Picoeukaryote-based biohybrid microrobots for active delivery in the kidney
Science Advances · 2025
- Strength of evidence supporting cancer drug approvals in China between 2017 and 2021: a retrospective analysis
The Lancet Oncology · 2025
- Online estimation and inference for robust policy evaluation in reinforcement learning
The Annals of Statistics · 2025
- Practice and Exploration of Wall Painting to Help Rural Revitalization--Taking the Activities of "Art and Youth" Cultural Art Troupe as an Example
Frontiers in Humanities and Social Sciences · 2025
- Strength of evidence supporting cancer drug approvals in China, 2017-2021.
Journal of Clinical Oncology · 2025
- Multiple ctDNA- based biomarkers predict benefit from selective RET Inhibition in non-small cell lung cancer patients: exploratory analysis of a prospective study
Biomarker Research · 2025
- Associations between clinical benefits of cancer drugs and incremental quality-adjusted life years used in reimbursement decisions in Australia, Canada, England and China: an observational study
BMJ Open · 2025
- Assessing the risks and benefits of investigational new drugs in adult phase-I oncology trials in China, 2013–2021
Investigational New Drugs · 2025
- Evolution of evidence on overall survival benefits of cancer drugs included on the national reimbursement drug list of China, 2005–2022: an observational study
BMJ evidence-based medicine · 2025
- Ongoing Development of Online Tone and Intonation Recognition in Mandarin During Late Childhood
Journal of Speech Language and Hearing Research · 2025
- Costs and benefits of early access to new cancer drugs through the US Food and Drug Administration’s accelerated approval pathway: retrospective observational study and economic evaluation
BMJ Medicine · 2025
- Overall survival benefits of cancer drugs initially approved by the US Food and Drug Administration on the basis of immature survival data: a retrospective analysis
The Lancet Oncology · 2024
- Prevalence of aggressive care among patients with cancer near the end of life: a systematic review and meta-analysis
EClinicalMedicine · 2024
- Correlation of distribution characteristics and dynamic changes of gut microbiota with the efficacy of immunotherapy in EGFR-mutated non-small cell lung cancer
Journal of Translational Medicine · 2024
- Journal of Thoracic Oncology×4
- JAMA Network Open×3
- BMJ Open×3
- SSRN Electronic Journal×3
- The Lancet Oncology×2
- Nasser H. Hanna
Medicine · Indiana University
- Nobuyuki Yamamoto
Medicine · Indiana University
- Gregory A. Otterson
Medicine · The Ohio State University
- Ai Ni
Medicine · The Ohio State University
- Tamio Okimoto
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile